Treatment of visceral leishmaniasis: options and choice-Reference-Cited by-同舟云学术

Treatment of visceral leishmaniasis: options and choice

Published:2016-02 Issue:2 Volume:16 Page:142-143
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Bhattacharya Sujit K,Dash Aditya Prasad

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference13 articles.

1. Occurrence & significance of kala-azar in Bhutan;Bhattacharya;Indian J Med Res,2010

2. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable;Bhattacharya;Indian J Med Res,2006

3. Trial of oral miltefosine for visceral leishmaniasis;Sundar;Lancet,1998

4. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis;Jha;N Engl J Med,1999

5. Short-course of oral miltefosine for treatment of visceral leishmaniasis;Sundar;Clin Infect Dis,2000

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis;Frontiers in Immunology;2022-05-02

2. Donor acquired visceral leishmaniasis following liver transplantation;Frontline Gastroenterology;2021-01-04

3. Physicochemical characterization and in vitro biological evaluation of solid compounds from furazolidone-based cyclodextrins for use as leishmanicidal agents;Drug Delivery and Translational Research;2020-08-16

4. Visceral Leishmaniasis;Leishmaniases as Re-emerging Diseases;2018-10-10

5. Physicochemical and in vitro biological evaluations of furazolidone-based β-cyclodextrin complexes in Leishmania amazonensis;Research in Veterinary Science;2018-08